Apr 27, 2016

Posted by in Biotech Stocks | 0 Comments

Investor’s Watch List: BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), ZIOPHARM Oncology Inc (NASDAQ:ZIOP), Hemispherx BioPharma Inc (NYSEMKT:HEB)

Investor’s Watch List: BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), ZIOPHARM Oncology Inc (NASDAQ:ZIOP), Hemispherx BioPharma Inc (NYSEMKT:HEB)

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) plunged -5.79% and ended at $3.42. The total traded volume was 2.15 million shares and market capitalization arrived at $265.16 million. The stock has a 52-week high price of $16.83 and its 52-week low was recorded at $1.63, while during last trade its minimum price was $3.10 and it gained the highest price of $3.73.

BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) on April 21, 2016 announced that its first quarter 2016 financial results will be released on Thursday, May 5, 2016.  BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial results and to provide an update regarding the Company’s clinical development programs.  The call will be led by Jon P. Stonehouse, President and Chief Executive Officer, Thomas R. Staab, II, Senior Vice President and Chief Financial Officer and Dr. William P. Sheridan, Senior Vice President and Chief Medical Officer.

ZIOPHARM Oncology Inc (NASDAQ:ZIOP) reported the increase of +0.75% to close at $8.10 with the overall traded volume of 2.09 million shares. Its market capitalization on last close reached to $1.06 billion. Its beta value stands at 1.69 times. The company has the total of 131.72 million outstanding shares. Its intraday-low price was $7.81 and its hit its day’s highest price at $8.19.

ZIOPHARM Oncology Inc (NASDAQ:ZIOP) on April 18, 2016 announced results from two programs will be presented in oral sessions at the upcoming 19th Annual American Society of Gene and Cell Therapy (ASGCT) Meeting. The first presentation highlights preclinical data from the Company’s novel viral gene therapy candidate for the controlled expression of IL-12 in combination with inhibition of programmed cell death protein 1 (PD-1) in a mouse model of glioma. The second presentation highlights preclinical data from the Company’s evolution of the Sleeping Beauty (SB) non-viral transposon-transposase system in a mouse model of leukemia. The ASGCT meeting will take place May 4-7 at the Marriott Wardman Park Hotel in Washington, D.C.

Hemispherx BioPharma Inc (NYSEMKT:HEB) moved up +12.98% to settle at $0.154. Its total traded volume during last trading session was 2.09 million shares. The overall market worth of this company is about $38.55 million. The 52 week range of the stock remained $0.06 – $0.29, while its day’s lowest price was $0.14 and its hit its day’s highest price at $0.16. The beta of this stock currently stands at 0.57.

Hemispherx BioPharma Inc (NYSEMKT:HEB) on April 20, 2016 announced that it has signed a consulting agreement with Huron Consulting Group, a global consultancy with decades of experience in the life sciences market,  to advance the company’s strategic plan to capitalize on business opportunities in the United States and in target countries around the world.

Huron Consulting Group provides a wide variety of advisory and professional services encompassing the entire scope of the life sciences and healthcare industries from investment, research, and strategic planning to commercialization and mergers and acquisitions.  “Our agreement with Huron is an important part in the new direction for our company.  Huron will provide us the strategic guidance and established connections critical to our quest for powerful co-development partners,” said Thomas K. Equels, CEO of Hemispherx Biopharma.

 

Comments are closed.